



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Not Yet Assigned

35 U.S.C. 371 after June 30, 2003. The present application was filed after June 30, 2003. Pursuant to this Notice, copies of the U.S. patents and U.S. patent application publications cited in the accompanying PTO/SB/O8 are not submitted herewith

I hereby certify that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

A copy of each document on the PTO/SB/O8 is attached.

A concise explanation of relevance of the items listed on form PTO/SB/O8 is given.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated:

Respectfully submitted,

By

Paul M. Zagar

Registration No.: 52,392

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 753-6237 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/797,626
				Filing Date	March 9, 2004
				First Named Inventor	Peter C. Brooks
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	05986/100M228-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-5,092,885-B1	03-03-1992	Yamada et al.	
	AB	US-5,112,946-B1	05-12-1992	Maione	
	AC	US-5,192,744-B1	03-09-1993	Bouck et al.	
	AD	US-5,202,352-B1	04-13-1993	Okada et al	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO 00/40597	07-13-2000	University of Southern California		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Amstutz, et al., <i>In vitro</i> display technologies: novel developments and applications. Current Opinion in Biotechnology 2001;12:400-405	
	2	Blood, et al., Biochim. Biophys. Acta. 1990;1032:89-118	
	3	Brooks, et al., J Clin. Invest. 1995;96:1815-1822.	
	4	Brooks, et al., Cell 1994;79:1157-1164	
	5	Brooks, et al., Cell 1998;92:391-400	
	6	Green, et al., Proc. Natl. Acad. Sci. USA 2003;100:1010-1015	
	7	Guo, et al., In vitro evolution of amphioxus insulin-like peptide to mammalian insulin. Biochemistry 2002;41:10603-10607	
	8	Hangai, et al., Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. American Journal of Pathology 2002;161(4):1429-1437.	
	9	Heeley RP, Endocr. Res. 2002;28:217-229	
	10	Kurschat, et al., Clin. Exp. Dermatol. 2000;25:482-489	
	11	Liljeblad, et al., Analysis of agalacto-IgG in rheumatoid arthritis using surface plasmon resonance. Glycoconjugate Journal 2000;17:323-329	
	12	Liotta, et al., Cell 1991;64:327-336	
	13	Roskelly, et al., Curr. Op. Cell Biol. 1995;7:736-747	
	14	Stephanopoulos G, Metabolic engineering by genome shuffling. Nature Biotechnology 2002;20(7):666-668	
	15	Tani, et al., In vitro selection o fibronectin gain-of-function mutations. Biochem. J. 2002;365:287-294	
	16	Varner, et al., Cell Adh. Commun. 1995;3:367-374	
	17	Xu, et al., Generation of monoclonal antibodies to cryptic collagen sites by using subtractive	

W:1059
86/100Date
Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/797,626
				Filing Date	March 9, 2004
				First Named Inventor	Peter C. Brooks
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	1	Attorney Docket Number	05986/100M228-US1

		immunization. Hybridoma 2000;19(5)375-385	
	18	Xu, et al., Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. Journal of Cell Biology 2001;154(5):1069-1079	
	19	Weidner, et al., J. Natl. Cancer Inst. 1992;84:1875-1887	
	20	Weidner, et al., N. Engl. J Med. 1991;324:1-7	
	21	Wyckoff, et al., Cancer Res. 2000;60:2504-2511	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

{W:1059 861100		Date Considered	
-------------------	--	--------------------	--